Attached files

file filename
8-K - CURRENT REPORT - LCA VISION INCd339058d8k.htm

Exhibit 99.1

 

LOGO

News Release

LCA-Vision First Quarter Results Feature EPS of $0.20

Revenues Increase 12%, Procedure Volume Up 11%

CINCINNATI (April 24, 2012) – LCA-Vision Inc. (NASDAQ: LCAV), a leading provider of laser vision correction services under the LasikPlus® brand, today announced financial and operating results for the three months ended March 31, 2012.

First Quarter 2012 Financial and Operating Highlights (all comparisons are with the first quarter of 2011)

 

   

Revenues increased 11.9% to $36.1 million from $32.3 million; adjusted revenues increased 13.9% to $35.3 million from $31.0 million.

 

   

Total procedure volume increased 11.3% to 20,987 procedures from 18,857 procedures.

 

   

Operating income increased to $3.8 million from $2.0 million; adjusted operating income increased to $3.0 million from $0.8 million. The improvement in operating income and adjusted operating income reflects higher procedure revenue offset partially by increases in variable costs, additional spending on marketing and advertising, and increases in general and administrative costs.

 

   

Marketing cost per eye decreased to $326 from $344.

 

   

Net income was $3.8 million, or $0.20 per share, compared with net income of $2.0 million, or $0.11 per share.

 

   

Net cash provided by operations was $4.5 million compared with $4.8 million. Although net income increased substantially for the first quarter of 2012, changes in working capital resulted in a reduction of cash from operations in the first quarter of 2012 compared with a source of cash in the prior year.

 

   

Cash and investments increased by $3.5 million to $48.3 million as of March 31, 2012, compared with $44.8 million as of December 31, 2011.

The company provides adjusted revenues and operating income as a means of measuring performance that adjusts for the non-cash impact of accounting for separately priced extended warranties. A reconciliation of revenues and operating income as reported in accordance with U.S. Generally Accepted Accounting Principles (GAAP) is provided at the end of this news release. Management believes that the adjusted information better reflects operating performance and, therefore, is more meaningful to investors.

“We are pleased to report a profitable quarter, which reflects seasonally strong procedure volume as patients take advantage of flexible spending programs in the first quarter,” said LCA-Vision Chief Financial Officer Michael J. Celebrezze. “Additionally, we benefited from a modest improvement in the Consumer Confidence Present Situation Index, which historically has correlated closely with our procedure volume. However, we continue to believe the index remains below the level at which consumers are comfortable with discretionary spending on medical procedures.


“Importantly, we are reporting double-digit growth in revenues and procedure volume compared with the prior year and a 90% increase in net income. Even with the $500 discount promotion we offered during most of the first quarter, average price per procedure of $1,683 was $38 higher than the first quarter of 2011 and was $25 above the price for the fourth quarter of 2011. In reviewing our operating metrics compared with the prior year, our preoperative appointment show rate was considerably higher.”

LCA-Vision Chief Operating Officer David L. Thomas said, “We are firmly focused on continued improvements in our laser vision correction services business. Currently, we are optimizing marketing activities at the local level and working to align staff with increases in preoperative exams in certain centers. We see ample opportunity for growth in our laser vision correction business as the economy gains momentum. Our vision center staff and call center team are delivering a high level of patient satisfaction which results in word of mouth referrals to LasikPlus®.

“In addition to improving our core business, we have a well-defined, multi-part strategy to promote future growth and profitability. We are expanding our affiliate network of key eye-care professionals for LASIK and cataract patient referrals beyond our direct-to-consumer model, and we recently hired a vice president to oversee this function. We also are implementing a marketing and operational plan to support a successful expansion into cataract and premium intraocular lens (IOL) surgery under our new Visium Eye Institute™ brand. We are on track to have this offering available in 10 to 14 markets by the end of 2012. We see significant long-term opportunity with this offering as the cataract and premium IOL market is four times as large as laser vision correction, although, as previously announced, we expect to incur start-up losses associated with our business expansion.”

Near-term Financial Outlook

LCA-Vision intends to continue to manage expenses conservatively in 2012; its plans and outlook for the year include:

 

   

The company does not plan to open any new vision centers in the near term. LCA-Vision will consider restarting its de novo vision center opening program when market conditions improve and the company moves closer to sustained profitability in its core laser vision correction services business.

 

   

The company anticipates a modest improvement in price per procedure from the 2011 average of $1,655.

 

   

The company expects marketing and advertising expenses for the 2012 second quarter to be between $6.8 million and $7.3 million.

 

   

The company expects capital expenditures in 2012 to be between $2.0 million and $2.5 million for cataract-related equipment and other capital needs.

The company affirms that the number of procedures companywide required for its laser vision correction business to achieve breakeven cash flow, after capital expenditures and debt service, remains approximately 70,000 per year. The company expects to incur start-up losses and capital investment during the expansion phase for its cataract and IOL business.

Conference Call and Webcast

As previously announced, a conference call and webcast will be held today beginning at 10:00 a.m. Eastern time. To access the conference call, dial 866-322-1352 (U.S. and Canada) or 706-643-6246 (international callers). The webcast will also be available in the investor relations section of LCA-Vision’s website. A replay of the call and webcast will begin approximately two hours after the live call has ended. To access the replay, dial 855-859-2056 (U.S. and Canada) or 404-537-3406 (international callers) and enter the conference ID number: 59649604.

 

2


Forward-Looking Statements

This news release contains forward-looking statements based on current expectations, forecasts and assumptions of LCA-Vision that are subject to risks and uncertainties. The forward-looking statements in this release are based on information available to the company as of the date hereof. Actual results could differ materially from those stated or implied in the forward-looking statements due to risks and uncertainties associated with its business. In addition to the risk factors discussed in the company’s Form 10-K and other filings with the Securities and Exchange Commission, there are a number of other risks and uncertainties associated with its business including, without limitation, the successful execution of cost effective marketing strategies to drive patients to its vision centers; the impact of low consumer confidence and discretionary spending; competition in the laser vision correction industry; the company’s ability to attract patients; the possibility of adverse outcomes or long-term side effects of laser vision correction and negative publicity regarding laser vision correction; the company’s ability to operate profitable vision centers and retain qualified personnel during periods of lower procedure volumes; the company’s success in expanding its services into the cataract and IOL market; the continued availability of non-recourse third-party financing for its patients on terms similar to what it has paid historically; and the future value of revenues financed by the company and its ability to collect on such financings, which will in turn depend on a number of factors, including the consumer credit environment and the company’s ability to manage credit risk related to consumer debt, bankruptcies and other credit trends.

Further, the Food and Drug Administration’s (FDA) advisory board on ophthalmic devices currently is reviewing concerns about post-LASIK quality of life matters, and the FDA has undertaken a study on LASIK outcomes and quality of life that is expected to end in 2012. The FDA or another regulatory body could take legal or regulatory action against the company or others in the laser vision correction industry. The outcome of this review or legal or regulatory action could potentially impact negatively the acceptance of LASIK. In addition, the acceptance rate of new technologies and our ability to implement successfully new technologies on a national basis create additional risk.

Except to the extent required under the federal securities laws and the rules and regulations promulgated by the Securities and Exchange Commission, the company assumes no obligation to update the information included in this news release, whether as a result of new information, future events or circumstances, or otherwise.

About LCA-Vision Inc./LasikPlus®

LCA-Vision Inc., a leading provider of laser vision correction services under the LasikPlus® brand, operates 52 LasikPlus® fixed-site laser vision centers in 26 states and 41 markets in the United States. Additional company information is available at www.lca-vision.com and www.lasikplus.com.

Earning Trust Every Moment; Transforming Lives Every Day.

For Additional Information

 

Company Contact:   Investor Relations Contact:
Barb Kise   Jody Cain
LCA-Vision Inc.   LHA
513-792-9292   310-691-7100 – jcain@lhai.com
  @LHA_IR_PR

 

3


LCA-Vision Inc.

Condensed Consolidated Balance Sheets (Unaudited)

(Dollars in thousands)

 

     March 31, 2012     December 31, 2011  

Assets

    

Current assets

    

Cash and cash equivalents

   $ 22,914      $ 18,568   

Short-term investments

     24,520        25,311   

Patient receivables, net of allowances of $1,002 and $1,035

     2,895        2,366   

Other accounts receivable, net

     2,945        1,974   

Prepaid expenses and other

     3,714        4,254   
  

 

 

   

 

 

 

Total current assets

     56,988        52,473   

Property and equipment, net

     9,389        10,637   

Long-term investments

     882        902   

Patient receivables, net of allowances of $719 and $634

     1,099        769   

Other assets

     1,349        1,652   
  

 

 

   

 

 

 

Total assets

   $ 69,707      $ 66,433   
  

 

 

   

 

 

 

Liabilities and Stockholders’ Investment

    

Current liabilities

    

Accounts payable

   $ 9,534      $ 8,103   

Accrued liabilities and other

     12,129        12,175   

Deferred revenue

     2,064        2,516   

Debt obligations maturing within one year

     3,015        2,978   
  

 

 

   

 

 

 

Total current liabilities

     26,742        25,772   

Long-term insurance reserves, less current portion

     6,183        6,264   

Long-term debt obligations, less current portion

     258        1,026   

Other long-term liabilities

     6,124        7,106   

Stockholders’ investment

    

Common stock ($.001 par value; 25,291,637 shares issued and 18,972,134 and 18,858,147 shares outstanding, respectively)

     25        25   

Contributed capital

     177,790        177,287   

Common stock in treasury, at cost (6,319,503 shares and 6,433,490 shares, respectively)

     (112,047     (112,910

Accumulated deficit

     (36,041     (38,720

Accumulated other comprehensive income

     673        583   
  

 

 

   

 

 

 

Total stockholders’ investment

     30,400        26,265   
  

 

 

   

 

 

 

Total liabilities and stockholders’ investment

   $ 69,707      $ 66,433   
  

 

 

   

 

 

 

 

4


LCA-Vision Inc.

Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited)

(Amounts in thousands except per share data)

 

     Three months ended March 31,  
     2012      2011  

Revenues

   $ 36,138       $ 32,282   

Operating costs and expenses

     

Medical professional and license fees

     8,682         7,983   

Direct costs of services

     11,911         11,020   

General and administrative expenses

     3,706         3,456   

Marketing and advertising

     6,851         6,496   

Depreciation

     1,312         1,454   

Restructuring charges

     —           56   
  

 

 

    

 

 

 
     32,462         30,465   

Gain on sale of assets

     78         163   
  

 

 

    

 

 

 

Operating income

     3,754         1,980   

Net investment income and other

     116         80   
  

 

 

    

 

 

 

Income before taxes

     3,870         2,060   

Income tax expense

     24         41   
  

 

 

    

 

 

 

Net income

   $ 3,846       $ 2,019   
  

 

 

    

 

 

 

Earnings per common share

     

Basic

   $ 0.20       $ 0.11   

Diluted

   $ 0.20       $ 0.11   

Weighted average shares outstanding

     

Basic

     18,895         18,743   

Diluted

     19,090         18,884   

Comprehensive income

   $ 3,936       $ 2,158   
  

 

 

    

 

 

 

 

5


LCA-Vision Inc.

Condensed Consolidated Statements of Cash Flows (Unaudited)

(Dollars in thousands)

 

     Three months ended March 31,  
     2012     2011  

Cash flows from operating activities:

    

Net income

   $ 3,846      $ 2,019   

Adjustments to reconcile net income to net cash provided by operating activities:

    

Depreciation

     1,312        1,454   

Provision for loss on doubtful accounts

     243        155   

Loss (gain) on sale of investments, net

     8        (10

Gain on sale of property and equipment

     (78     (163

Stock-based compensation

     504        375   

Insurance reserves

     (93     (205

Changes in operating assets and liabilities:

    

Patient accounts receivable

     (1,097     (290

Other accounts receivable

     (975     (370

Prepaid expenses and other

     449        1,406   

Accounts payable

     1,431        535   

Deferred revenue, net of professional fees

     (738     (1,142

Accrued liabilities and other

     (319     1,051   
  

 

 

   

 

 

 

Net cash provided by operations

     4,493        4,815   

Cash flows from investing activities:

    

Purchases of property and equipment

     (67     (634

Proceeds from sale of assets

     127        570   

Purchases of investment securities

     (32,203     (40,061

Proceeds from sale of investment securities

     32,929        42,267   

Other, net

     —          8   
  

 

 

   

 

 

 

Net cash provided by investing activities

     786        2,150   

Cash flows from financing activities:

    

Principal payments of loan

     (731     (979

Shares repurchased for treasury stock

     (357     (288

Proceeds from exercise of stock options

     52        23   
  

 

 

   

 

 

 

Net cash used in financing activities

     (1,036     (1,244
  

 

 

   

 

 

 

Net effect of exchange rate changes on cash and cash equivalents

     103        131   
  

 

 

   

 

 

 

Increase in cash and cash equivalents

     4,346        5,852   

Cash and cash equivalents at beginning of period

     18,568        19,350   
  

 

 

   

 

 

 

Cash and cash equivalents at end of period

   $ 22,914      $ 25,202   
  

 

 

   

 

 

 

 

6


LCA-Vision Inc.

Effect of the Change in Accounting for Deferred Revenues on Financial Results

(Dollars in thousands)

(Unaudited)

To supplement its Consolidated Financial Statements presented in accordance with accounting principles generally accepted in the United States, LCA-Vision discusses adjusted revenues and operating income. Management utilizes this information as a means of measuring performance that adjusts for the non-cash impact of the accounting for separately priced extended warranties and believes that including this additional disclosure is meaningful to investors for the same reason.

Accordingly, this news release contains non-GAAP financial measures within the meaning of Regulation G promulgated by the Securities and Exchange Commission. A reconciliation of the difference between the non-GAAP measures with the most directly comparable financial measures calculated in accordance with GAAP follows:

 

     Three months ended March 31,  
     2012     2011  

Revenues

    

Reported U.S. GAAP

   $ 36,138      $ 32,282   

Adjustments:

    

Amortization of prior deferred revenue

     (821     (1,269
  

 

 

   

 

 

 

Adjusted revenues

   $ 35,317      $ 31,013   
  

 

 

   

 

 

 

Operating Income

    

Reported U.S. GAAP

   $ 3,754      $ 1,980   

Adjustments:

    

Amortization of prior deferred revenue

     (821     (1,269

Amortization of prior professional fees

     82        127   
  

 

 

   

 

 

 

Adjusted operating income

   $ 3,015      $ 838   
  

 

 

   

 

 

 

# # #

 

7